An evidence-based review of the mechanism of action, efficacy, and safety of biologic therapies in the treatment of psoriasis and psoriatic arthritis

Current Medicinal Chemistry

Volumn 22, Issue 16, 2015, Pages 1930-1942

  Brezinski, Elizabeth A ^a   Armstrong, April W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Adalimumab; Biologics; Certolizumab pegol; Etanercept; Golimumab; Infliximab; Psoriasis; Psoriatic arthritis; Review; Ustekinumab

Indexed keywords

ADALIMUMAB; ANTIPSORIASIS AGENT; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 23; MONOCLONAL ANTIBODY; PROTEIN INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; BIOLOGICAL FACTOR;

ABDOMINAL PAIN; ABSCESS; ACUTE CHOLECYSTITIS; ARTHRALGIA; ATRIAL FIBRILLATION; BIOLOGICAL THERAPY; BREAST CANCER; CELLULITIS; COLON CANCER; COLORECTAL CANCER; CORONARY ARTERY DISEASE; CUTANEOUS; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DIVERTICULITIS; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG INFORMATION; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; FATIGUE; HEART DISEASE; HEART INFARCTION; HODGKIN DISEASE; HUMAN; INFECTION; INFUSION RELATED REACTION; LEUKEMIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NON MELANOMA SKIN CANCER; OFF LABEL DRUG USE; PHARYNGITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROSTATE CANCER; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHINOPHARYNGITIS; SEPSIS; SMALL CELL LUNG CANCER; SUPERFICIAL THROMBOPHLEBITIS; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINE INCONTINENCE; ARTHRITIS, PSORIATIC;

ARTHRITIS, PSORIATIC; BIOLOGICAL FACTORS; HUMANS; PSORIASIS;

EID: 84931281919     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150429111804     Document Type: Review

References (76)

1. Rachakonda, T.D.; Schupp, C.W.; Armstrong, A.W. Psoriasis Prevalence among Adults in the United States. J. Am. Acad. Dermatol., 2014, 70(3), 512-516.
2. Gelfand, J.M.; Gladman, D.D.; Mease, P.J.; Smith, N.; Margolis, D.J.; Nijsten, T.; Stern, R.S.; Feldman, S.R.; Rolstad, T. Epidemiology of psoriatic arthritis in the population of the United States. J. Am. Acad. Dermatol., 2005, 53(4), 573.
3. Javitz, H.S.; Ward, M.M.; Farber, E.; Nail, L.; Vallow, S.G. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J. Am. Acad. Dermatol., 2002, 46(6), 850-860.
4. Kimball, A.B.; Jacobson, C.; Weiss, S.; Vreeland, M.G.; Wu, Y. The psychosocial burden of psoriasis. Am J. Clin. Dermatol., 2005, 6(6), 383-392.
5. Kimball, A.B.; Guerin, A.; Tsaneva, M.; Yu, A.P.; Wu, E.Q.; Gupta, S.R.; Bao, Y.; Mulani, P.M. Economic burden of comorbidities in patients with psoriasis is substantial. J. Eur. Acad. Dermatol. Venereol., 2011, 25(2), 157-163.
6. Han, C.; Lofland, J.H.; Zhao, N.; Schenkel, B. Increased prevalence of psychiatric disorders and health care-associated costs among psoriasis patients with moderate-to-severe psoriasis. J. Drugs Dermatol., 2011, 10(8), 843-850.
7. Partsch, G.; Steiner, G.; Leeb, B.F.; Dunky, A.; Broll, H.; Smolen, J.S. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J. Rheumatol., 1997, 24(3), 518-523.
8. Ettehadi, P.; Greaves, M.W.; Wallach, D.; Aderka, D.; Camp, R.D. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin. Exp. Immunol., 1994, 96(1), 146-151.
9. Hu, S.; Liang, S.; Guo, H.; Zhang, D.; Li, H.; Wang, X.; Yang, W.; Qian, W.; Hou, S.; Wang, H.; Guo, Y.; Lou, Z. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor alpha-associated diseases from a molecular view. J. Biol. Chem., 2013, 288(38), 27059-27067.
10. Armstrong, A.W.; Voyles, S.V.; Armstrong, E.J.; Fuller, E.N.; Rutledge, J.C. A tale of two plaques: convergent mechanisms of Tcell-mediated inflammation in psoriasis and atherosclerosis. Exp. Dermatol., 2011, 20(7), 54454-9.
11. Enbrel (etanercept) [package insert]; Seattle, WA: Immunex Corporation, 2013.
12. Yawalkar, N.; Karlen, S.; Hunger, R.; Brand, C.U.; Braathen, L.R. Expression of interleukin-12 is increased in psoriatic skin. J. Invest. Dermatol., 1998,111(6), 1053-7.
13. Piskin, G.; Sylva-Steenland, R.M.; Bos, J.D.; Teunissen, M.B. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J. Immunol., 2006, 176(3), 1908-1915.
14. Gottlieb, A.B.; Evans, R.; Li, S.; Dooley, L.T.; Guzzo, C.A.; Baker, D.; Bala, M.; Marano, C.W.; Menter, A. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol., 2004, 51(4), 534-542.
15. Reich, K.; Nestle, F.O.; Papp, K.; Ortonne, J.P.; Evans, R.; Guzzo, C.; Li, S.; Dooley, L.T.; Griffiths, C.E. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet, 2005, 366(9494), 1367-1374.
16. Leonardi, C.L.; Powers, J.L.; Matheson, R.T.; Goffe, B.S.; Zitnik, R.; Wang, A.; Gottlieb, A.B. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med., 2003, 349(21), 2014-2022.
17. Aggarwal, S.; Ghilardi, N.; Xie, M.H.; Sauvage, F.J.; Gurney, A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem., 2003, 278(3), 1910-1914.
18. Pariser, D.M.; Bagel, J.; Gelfand, J.M.; Korman, N.J.; Ritchlin, C.T.; Strober, B.E.; Van Voorhees, A.S.; Young, M.; Rittenberg, S.; Lebwohl, M.G.; Horn, E.J. National Psoriasis Foundation clinical consensus on disease severity. Arch. Dermatol., 2007, 143(2), 239-242.
19. Menter, A.; Korman, N.J.; Elmets, C.A.; Feldman, S.R.S.; Gelfand, J.M.; Koo, J.K.; Lebwohl, M.; Leonardi, C.L.; Lim, H.W.; Van Voorhees, A.S.; Beutner, K.R.; Ryan, C.; Bhushan, R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J. Am. Acad. Dermatol., 2009, 61(3), 451-485.
20. Menter, A.; Korman, N.J.; Elmets, C.A.; Feldman, S.R.S.; Gelfand, J.M.; Koo, J.K.; Lebwohl, M.; Leonardi, C.L.; Lim, H.W.; Van Voorhees, A.S.; Beutner, K.R.; Ryan, C.; Bhushan, R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J. Am. Acad. Dermatol., 2011, 65(1), 137-174.
21. Feldman, S.R.; Krueger, G.G. Psoriasis assessment tools in clinical trials. Ann. Rheum. Dis., 2005, 64(Suppl 2), ii65-ii68.
22. Fredriksson, T.; Pettersson, U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica, 1978, 157(4), 238-244.
23. Mrowietz, U.; Kragballe, K.; Reich, K.; Spuls, P.; Griffiths, C.E.M.; Nast, A.; Franke, J.; Antoniou, C.; Arenberger, P.; Balieva, F.; Bylaite, M.; Correia, O.; Dauden, E.; Gisondi, P.; Iversen, L.; Kemeny, L.; Lahfa, M.; Nijsten, T.; Rantanen, T.; Reich, A.; Rosenbach, T.; Segaert, S.; Smith, C.; Talme, T.; Volc-Platzer, B.; Yawalkar, N. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch. Dermatol. Res., 2011, 303(1), 1-10.
24. Baker, C.; Mack, A.; Cooper, A.; Fischer, G.; Shumack, S.; Sidhu, S.; Soyer, P.; Wu, J.; Chan, J.; Nash, P.; Rawlin, M.; Radulski, B.; Foley, P. Treatment goals for moderate to severe psoriasis: an Australian consensus. Australas J. Dermatol., 2013, 54(2), 148-154.
25. Hsu, S.; Papp, K.A.; Lebwohl, M.G.; Bagel, J.; Blauvelt, A.; Duffin, K.C.; Crowley, J.; Eichenfield, L.F.; Feldman, S.R.; Fiorentino, D.F.; Gelfand, J.M.; Gottlieb, A.B.; Jacobsen, C.; Kalb, R.E.; Kavanaugh, A.; Korman, N.J.; Krueger, G.G.; Michelon, M.A.; Morison, W.; Ritchlin, C.T.; Stein Gold, L.; Stone, S.P.; Strober, B.E.; Van Voorhees, A.S.; Weiss, S.C.; Wanat, K.; Bebo, B.F., Jr. Consensus guidelines for the management of plaque psoriasis. JAMA Dermatol., 2012, 148(1), 95-102.
26. Puig, L.; Bordas, X.; Carrascosa, J.M.; Dauden, E.; Ferrandiz, C.; Hernanz, J.M.; Lopez-Estebaranz, J.L.; Moreno, J.C.; Sanchez-Carazo, J.L.; Vanaclocha, F.; Vazquez-Veiga, H. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr., 2009, 100(4), 277-286.
27. Papp, K.; Gulliver, W.; Lynde, C.; Poulin, Y.; Ashkenas, J. Canadian guidelines for the management of plaque psoriasis: overview. J .Cutan. Med. Surg., 2011, 15(4), 210-219.
28. Felson, D.T.; Anderson, J.J.; Boers, M.; Bombardier, C.; Furst, D.; Goldsmith, C.; Katz, L.M.; Lightfoot, R., Jr.; Paulus, H.; Strand, V.; et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum., 1995, 38(6), 727-735.
29. Mease, P.J.; Antoni, C.E.; Gladman, D.D.; Taylor, W.J. Psoriatic arthritis assessment tools in clinical trials. Ann. Rheum. Dis., 2005, 64(Suppl 2), ii49-ii54.
30. Mitoma, H.; Horiuchi, T.; Tsukamoto, H.; Tamimoto, Y.; Kimoto, Y.; Uchino, A.; To, K.; Harashima, S.; Hatta, N.; Harada, M. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum., 2008, 58(5), 1248-1257.
31. Tracey, D.; Klareskog, L.; Sasso, E.J.; Salfeld, J.G.; Tak, P.P. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol. Ther., 2008,117(2), 244-79.
32. Papp, K.A.; Tyring, S.; Lahfa, M.; Prinz, J.; Griffiths, C.E.; Nakanishi, A.M.; Zitnik, R.; van de Kerkhof, P.C.; Melvin, L. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol., 2005, 152(6), 1304-1312.
33. Leonardi, C.; Strober, B.; Gottlieb, A.B.; Elewski, B.E.; Ortonne, J.P.; van de Kerkhof, P.; Chiou, C.F.; Dunn, M.; Jahreis, A. Longterm safety and efficacy of etanercept in patients with psoriasis: an open-label study. J. Drugs Dermatol., 2010, 9(8), 928-937.
34. Papp, K.A.; Poulin, Y.; Bissonnette, R.; Bourcier, M.; Toth, D.; Rosoph, L.; Poulin-Costello, M.; Setterfield, M.; Syrotuik, J. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J. Am. Acad. Dermatol., 2012, 66(2), e33-e45.
35. Moore, A.; Gordon, K.; Kang, S.; Gottlieb, A.; Freundlich, B.; Xia, H.; Stevens, S. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J. Am. Acad. Dermatol., 2007, 56(4), 598-603.
36. Cassano, N.; Loconsole, F.; Miracapillo, A.; Travaglini, M.; Digiuseppe, M.D.; Congedo, M.; Galluccio, A.; Buquicchio, R.; Mastrandrea, V.; Filieri, M.; Raho, G.; Pezza, M.; Vena, G.A. Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Talpharanta Plastic Study Group. Int. J. Immunopathol. Pharmacol., 2010, 23(3), 797-802.
37. Ortonne, J.P.; Taieb, A.; Ormerod, A.D.; Robertson, D.; Foehl, J.; Pedersen, R.; Molta, C.; Freundlich, B. Patients with moderate-tosevere psoriasis recapture clinical response during re-treatment with etanercept. Br. J. Dermatol., 2009, 161(5), 1190-1195.
38. Mease, P.J.; Goffe, B.S.; Metz, J.; VanderStoep, A.; Finck, B.; Burge, D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet, 2000, 356(9227), 385-390.
39. Mease, P.J.; Kivitz, A.J.; Burch, F.X.; Siegel, E.L.; Cohen, S.B.; Ory, P.; Salonen, D.; Rubenstein, J.; Sharp, J.T.; Tsuji, W. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum., 2004, 50(7), 2264-2272.
40. Saougou, I.; Markatseli, T.E.; Papagoras, C.; Voulgari, P.V.; Alamanos, Y.; Drosos, A.A. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: A 5-year open-label observational cohort study. Semin. Arthritis. Rheum., 2011, 40(5), 398-406.
41. Kimball, A.B.; Pariser, D.; Yamauchi, P.S.; Menter, A.; Teller, C.F.; Shi, Y.; Yong, M.; Creamer, K.; Hooper, M.; Aras, G.; Kricorian, G.; Gelfand, J.M. OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. J. Am. Acad. Dermatol., 2013, 68(5), 756-764.
42. Remicade (infliximab) [package insert]; Malvery, PA: Centocor Inc, 2013.
43. Antoni, C.E.; Kavanaugh, A.; van der Heijde, D.; Beutler, A.; Keenan, G.; Zhou, B.; Kirkham, B.; Tutuncu, Z.; Burmester, G.R.; Schneider, U.; Furst, D.E.; Molitor, J.; Keystone, E.; Gladman, D.D.; Manger, B.; Wassenberg, S.; Weier, R.; Wallace, D.J.; Weisman, M.H.; Kalden, J.R.; Smolen, J.S. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J. Rheumatol., 2008, 35(5), 869-876.
44. Antoni, C.; Krueger, G.G.; de Vlam, K.; Birbara, C.; Beutler, A.; Guzzo, C.; Zhou, B.; Dooley, L.T.; Kavanaugh, A. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis., 2005, 64(8), 1150-1157.
45. Antoni, C.E.; Kavanaugh, A.; Kirkham, B.; Tutuncu, Z.; Burmester, G.R.; Schneider, U.; Furst, D.E.; Molitor, J.; Keystone, E.; Gladman, D.; Manger, B.; Wassenberg, S.; Weier, R.; Wallace, D.J.; Weisman, M.H.; Kalden, J.R.; Smolen, J. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum., 2005, 52(4), 1227-1236.
46. Humira (adalimumab) [package insert]; North Chicago, IL. Abbott Laboratories, 2013.
47. Menter, A.; Tyring, S.K.; Gordon, K.; Kimball, A.B.; Leonardi, C.L.; Langley, R.G.; Strober, B.E.; Kaul, M.; Gu, Y.; Okun, M.; Papp, K. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J. Am. Acad. Dermatol., 2008, 58(1), 106-115.
48. Gordon, K.; Papp, K.; Poulin, Y.; Gu, Y.; Rozzo, S.; Sasso, E.H. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J. Am. Acad. Dermatol., 2012, 66(2), 241-251.
49. Mease, P.J.; Gladman, D.D.; Ritchlin, C.T.; Ruderman, E.M.; Steinfeld, S.D.; Choy, E.H.; Sharp, J.T.; Ory, P.A.; Perdok, R.J.; Weinberg, M.A. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a doubleblind, randomized, placebo-controlled trial. Arthritis Rheum., 2005, 52(10), 3279-3289.
50. Mease, P.J.; Ory, P.; Sharp, J.T.; Ritchlin, C.T.; Van den Bosch, F.; Wellborne, F.; Birbara, C.; Thomson, G.T.; Perdok, R.J.; Medich, J.; Wong, R.L.; Gladman, D.D. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann. Rheum. Dis., 2009, 68(5), 702-709.
51. Gladman, D.D.; Mease, P.J.; Ritchlin, C.T.; Choy, E.H.; Sharp, J.T.; Ory, P.A.; Perdok, R.J.; Sasso, E.H. Adalimumab for longterm treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum., 2007, 56(2), 476-488.
52. Leonardi, C.; Papp, K.; Strober, B.; Reich, K.; Asahina, A.; Gu, Y.; Beason, J.; Rozzo, S.; Tyring, S. The long-term safety of adalimumab treatment in moderate to severe psoriasis: A comprehensive analysis of all adalimumab exposure in all clinical trials. Am. J. Clin. Dermatol., 2011, 12(5), 321-337.
53. Simponi (golimumab) [package insert]; Horsham, PA: Janssen Biotech, Inc. 2013.
54. Wagner, C.L.; Visvanathan, S.; Elashoff, M.; McInnes, I.B.; Mease, P.J.; Krueger, G.G.; Murphy, F.T.; Papp, K.; Gomez-Reino, J.J.; Mack, M.; Beutler, A.; Gladman, D.; Kavanaugh, A. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann. Rheum. Dis., 2013, 72(1), 83-88.
55. Kavanaugh, A.; McInnes, I.; Mease, P.; Krueger, G.G.; Gladman, D.; Gomez-Reino, J.; Papp, K.; Zrubek, J.; Mudivarthy, S.; Mack, M.; Visvanathan, S.; Beutler, A. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum., 2009, 60(4), 976-986.
56. Kavanaugh, A.; van der Heijde, D.; McInnes, I.B.; Mease, P.; Krueger, G.G.; Gladman, D.D.; Gomez-Reino, J.; Papp, K.; Baratelle, A.; Xu, W.; Mudivarthy, S.; Mack, M.; Rahman, M.U.; Xu, Z.; Zrubek, J.; Beutler, A. Golimumab in psoriatic arthritis: oneyear clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum., 2012, 64(8), 2504-2517.
57. Cimizia (certolizumab) [package insert]; Smyrna, GA: UCB, Inc., b. 2013.
58. Mease, P.J.; Fleischmann, R.; Deodhar, A.A.; Wollenhaupt, J.; Khraishi, M.; Kielar, D.; Woltering, F.; Stach, C.; Hoepken, B.; Arledge, T.; van der Heijde, D. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann. Rheum. Dis., 2014, 73(1), 48-55.
59. Stelara (ustekinumab) [package insert]; Horsham, PA: Centocor. Ortho Biotech. Inc., 2011.
60. Benson, J.M.; Peritt, D.; Scallon, B.J.; Heavner, G.A.; Shealy, D.J.; Giles-Komar, J.M.; Mascelli, M.A. Discovery and mechanism of ustekinumab: A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs, 2011, 3(6), 535-545.
61. Papp, K.A.; Langley, R.G.; Lebwohl, M.; Krueger, G.G.; Szapary, P.; Yeilding, N.; Guzzo, C.; Hsu, M.C.; Wang, Y.; Li, S.; Dooley, L.T.; Reich, K. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet, 2008, 371(9625), 1675-1684.
62. Leonardi, C.L.; Kimball, A.B.; Papp, K.A.; Yeilding, N.; Guzzo, C.; Wang, Y.; Li, S.; Dooley, L.T.; Gordon, K.B. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet, 2008, 371(9625), 1665-1674.
63. Griffiths, C.E.; Strober, B.E.; van de Kerkhof, P.; Ho, V.; Fidelus-Gort, R.; Yeilding, N.; Guzzo, C.; Xia, Y.; Zhou, B.; Li, S.; Dooley, L.T.; Goldstein, N.H.; Menter, A. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med., 2010, 362(2), 118-128.
64. McInnes, I.B.; Kavanaugh, A.; Gottlieb, A.B.; Puig, L.; Rahman, P.; Ritchlin, C.; Brodmerkel, C.; Li, S.; Wang, Y.; Mendelsohn, A.M.; Doyle, M.K. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet, 2013, 382(9894), 780-789.
65. Papp, K.A.; Griffiths, C.E.; Gordon, K.; Lebwohl, M.; Szapary, P.O.; Wasfi, Y.; Chan, D.; Hsu, M.C.; Ho, V.; Ghislain, P.D.; Strober, B.; Reich, K. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br. J. Dermatol., 2013, 168(4), 844-854.
66. De Felice, C.; Mazzotta, A.; Esposito, M.; Bianchi, L.; Chimenti, S. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life. J. Dermatolog. Treat., 2006, 17(6), 355-358.
67. Gordon, K.B.; Gottlieb, A.B.; Leonardi, C.L.; Elewski, B.E.; Wang, A.; Jahreis, A.; Zitnik, R. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J. Dermatol. Treat., 2006, 17(1), 9-17.
68. Chaudhari, U.; Romano, P.; Mulcahy, L.D.; Dooley, L.T.; Baker, D.G.; Gottlieb, A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet, 2001, 357(9271), 1842-1847.
69. Gottlieb, A.B.; Chaudhari, U.; Mulcahy, L.D.; Li, S.; Dooley, L.T.; Baker, D.G. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J. Am. Acad. Dermatol., 2003, 48(6), 829-835.
70. Menter, A.; Feldman, S.R.; Weinstein, G.D.; Papp, K.; Evans, R.; Guzzo, C.; Li, S.; Dooley, L.T.; Arnold, C.; Gottlieb, A.B. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-tosevere plaque psoriasis. J. Am. Acad. Dermatol., 2007, 56(1), 31 e1-e15.
71. Gordon, K.B.; Langley, R.G.; Leonardi, C.; Toth, D.; Menter, M.A.; Kang, S.; Heffernan, M.; Miller, B.; Hamlin, R.; Lim, L.; Zhong, J.; Hoffman, R.; Okun, M.M. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J. Am. Acad. Dermatol., 2006, 55(4), 598-606.
72. Leonardi, C.; Sobell, J.M.; Crowley, J.J.; Mrowietz, U.; Bao, Y.; Mulani, P.M.; Gu, Y.; Okun, M.M. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br. J. Dermatol., 2012, 167(3), 658-667.
73. Vena, G.A.; Galluccio, A.; De Simone, C.; Mastrandrea, V.; Buquicchio, R.; La Greca, S.; Dattola, S.; Puglisi Guerra, A.; Donato, L.; Cantoresi, F.; De Pita, O.; Pezza, M.; D Agostino, M.; Vernaci, R.; Miracapillo, A.; Valenti, G.; Cassano, N. A multicenter openlabel experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: The Aphrodite project. Int. J. Immunopathol. Pharmacol., 2009, 22(1), 227-233.
74. Cantini, F.; Niccoli, L.; Cassara, E.; Kaloudi, O.; Nannini, C. Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: A long-term followup study. Biologics, 2012, 6, 201-206.
75. Papp, K.; Crowley, J.; Ortonne, J.P.; Leu, J.; Okun, M.; Gupta, S.R.; Gu, Y.; Langley, R.G. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br. J. Dermatol., 2011, 164(2), 434-441.
76. Patel, D.D.; Lee, D.M.; Kolbinger, F.; Antoni, C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann. Rheum. Dis., 2013, 72(Suppl 2), ii116-123.